Introduction
============

Although notable advances have been made in the prevention, diagnosis and treatment of cancer, esophageal squamous cell carcinoma (OSCC) remains a significant global health burden, particularly in China, where \~70% of esophageal cancer is OSCC ([@b1-ol-0-0-6559]). OSCC is an aggressive cancer and the fourth most common cause of cancer-associated mortalities ([@b2-ol-0-0-6559],[@b3-ol-0-0-6559]). The progression of esophageal cancer is rapid, and there is a poor associated prognosis, with a 5-year overall survival rate of 10--42% ([@b4-ol-0-0-6559]--[@b6-ol-0-0-6559]). The association between genetic changes and clinical characteristics can reflect the biological events that promote OSCC invasion and metastasis, and the former may act as molecular tumor markers for diagnosis and prognosis. The principal driver of metastasis and invasion is epithelial-mesenchymal transition (EMT). Therefore, EMT-associated proteins are potentially useful diagnostic markers and therapeutic targets ([@b7-ol-0-0-6559]). The activation of EMT promotes tumor epithelial cells to dedifferentiate to a mesenchymal phenotype ([@b8-ol-0-0-6559]), during which cells gain the ability to penetrate the basement membrane and move to regional lymph nodes or distant organs ([@b8-ol-0-0-6559]). EMT-associated proteins have an important role in tumor progression, and a number of proteins are significantly associated with clinicopathological indexes ([@b9-ol-0-0-6559]). However, the EMT signalling network is extremely complex, and an improved understanding of the role that EMT-associated proteins have in this process may yield clinically useful information.

EMT, as demonstrated by the expression of EMT-associated proteins, has been reported in a number of different cancer types, including OSCC ([@b10-ol-0-0-6559]--[@b12-ol-0-0-6559]). Loss of epithelial (E-)cadherin expression and overexpression of zinc finger protein SNAI1, twist-related protein 1, testican-1, and receptor of activated protein kinase C1 has been reported to occur at the invasive front of OSCC, particularly in single or cords of tumor cells detaching from the main tumor mass ([@b13-ol-0-0-6559]--[@b18-ol-0-0-6559]). Although the expression of these EMT drivers have been well-researched in other cancer types, relatively little is known of their expression in OSCC ([@b19-ol-0-0-6559]).

Zinc finger E-box-binding homeobox 2 (ZEB2) is a transcription factor that can bind Smad proteins and contains multiple functional domains that interact with a variety of transcriptional co-effectors ([@b20-ol-0-0-6559]). ZEB2 directly binds adjacent E-boxes within the E-cadherin gene promoter and regulates transcriptional repression by recruiting corepressor complexes ([@b21-ol-0-0-6559]).

In the present study, immunohistochemistry (IHC) was performed to investigate the expression of the EMT-associated transcription factor ZEB2 and the cell adhesion protein E-cadherin in OSCC. It was observed that there were significant differences in the expression of ZEB2 and E-cadherin between OSCC and normal esophageal mucosa epithelial membrane, and multivariate analysis indicated that ZEB2 expression was an independent prognostic marker in OSCC.

Materials and methods
=====================

### Patients and tumor samples

All tissues were obtained from patients with OSCC (183 males and 35 females) who underwent esophagostomy without any preoperative therapy at the Department of Esophageal Oncology, Cancer Hospital of Tianjin Medical University (Tianjin, China), between June 2006 and June 2009. Histopathological diagnosis was determined according to the National Comprehensive Cancer Network (NCCN) guidelines ([@b22-ol-0-0-6559]). Informed consent was obtained from all patients, and ethical approval was obtained from the Institutional Review Board of the Cancer Hospital of Tianjin Medical University.

### Antibodies

A mouse anti-human monoclonal antibody against E-cadherin was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), and a rabbit anti-human polyclonal antibody against ZEB2 was obtained from Abcam (Cambridge, UK). The secondary antibodies were obtained from Shanghai Outdo Biotech Co., Ltd. (Shanghai, China).

### Construction of tissue microarray (TMA)

The thickness of the tissue section was 2 µm. The slides were evaluated by a senior pathologist to identify representative tumor areas. In brief, formalin-fixed, paraffin-embedded tissue blocks and the corresponding hematoxylin and eosin-stained slides were covered for TMA sampling. Multiple 0.6-mm diameter cylinders were punched from the representative tumor areas and from the adjacent peritumoral esophageal tissue using a tissue arrayer.

### IHC

The TMA slides used an isotype control. The TMA slides were dried overnight at 37°C, deparaffinized in xylene, rehydrated using a graded alcohol series and immersed in 3% hydrogen peroxide for 15 min to block endogenous peroxidase activity at 37°C. Antigen-retrieval was performed by heating to 100°C in a pressure cooker for 3 min in EDTA buffer (pH 8.0). Subsequently, the slides were incubated with rabbit polyclonal anti-ZEB2 (dilution, 1:100; catalog no. ab138222) that recognized only a single band corresponding to ZEB2, or mouse anti-E-cadherin (dilution, 1:50; catalog no. sc-59778) for 16 h at 4°C. The slides were subsequently incubated with a goat anti-rabbit immunoglobulin G conjugated to horseradish peroxidase (HRP) (dilution, 1:500; catalog no. abs20002A) for 1 h at 37°C and stained with 3,3-diaminobenzidine. Finally, the sections were counterstained with Mayer\'s hematoxylin, dehydrated and mounted. As a negative control, the primary antibody was replaced with KIT-9901 Elivision™ plus Polyer HRP (mouse/rabbit) IHC kit (Mai Xin Biotechnology Co., Ltd.). Patients with gastric cancer, from the Tianjin Medical University Cancer Institute and Hospital, which express ZEB2 were selected and used as a positive control.

### Evaluation of IHC staining

All tissues were observed using a CX41 light microscope (Olympus Corporation, Tokyo, Japan). All tissue sections were simultaneously assessed by two independent investigators, who were blinded to the patient clinicopathological details. The criteria for scoring ZEB2 and E-cadherin staining were as follows: Intensity was graded as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). The proportion of positive tumor cells was graded as 0 (\<5%), 1 (5--25%), 2 (26--50%), 3 (51--75%) or 4 (\>75%). A final score was derived by multiplying the two primary scores. Final scores of 0--4 were defined as negative expression (−), scores of 5--8 as weak positive expression (+) and scores of 9--12 as strong positive expression (++) ([@b23-ol-0-0-6559]).

### Statistical analysis

Statistical analyses were performed using SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA). The χ^2^ test was used to assess associations between ZEB2, E-cadherin and various clinicopathological variables. All factors were examined using univariate analysis and significant factors were further examined using multivariate analysis. Survival was analyzed using the Kaplan-Meier estimator method. The statistical significance of the association between ZEB2 and E-cadherin expression and overall survival was estimated using the log rank test. Multivariate Cox\'s proportional hazards regression was used to identify independent factors for overall survival. P\<0.05 was considered to indicate a statistically significant difference from a two-tailed test.

Results
=======

### Patients and baseline characteristics

The study group comprised 183 males and 35 females, with a median age of 67.6 years (range, 39--99 years). All patients had undergone macroscopically curative resection, and none had received any preoperative chemotherapy or radiotherapy. Pathologically, all tumors were squamous cell carcinoma. A total of 2,834 lymph nodes were resected from 218 patients, with a median of 13.0 nodes per patient.

### Expression of ZEB2 and E-cadherin in esophageal tissue

ZEB2 expression was observed in the cytoplasm of cancer cells. By contrast, E-cadherin expression was detected at the cell membrane ([Fig. 1](#f1-ol-0-0-6559){ref-type="fig"}). IHC analysis identified positive ZEB2 expression in 77 tumors (35.3%) and positive E-cadherin expression in 100 tumor s (45.9%). ZEB2 expression was significantly different between OSCCs and POTs in the patients (χ^2^=6.276; P\<0.05). Similar results were observed for E-cadherin expression (χ^2^=8.139; P\<0.05) ([Table I](#tI-ol-0-0-6559){ref-type="table"}).

### Association between ZEB2 and E-cadherin expression in OSCC and POT

E-cadherin membrane expression and a low level of ZEB2 expression were observed in normal esophageal epithelial tissues ([Fig. 2](#f2-ol-0-0-6559){ref-type="fig"}). IHC analysis identified positive ZEB2 expression in 11 POT cases (18.3%), and positive E-cadherin expression in 40 POT cases (66.7%) ([Table I](#tI-ol-0-0-6559){ref-type="table"}). Negative E-cadherin staining was detected in 53/77 (68.8%) cases positive for ZEB2 expression. Positive E-cadherin staining was detected in 76/141 (53.9%) cases negative for ZEB2 expression. Therefore, the expression of ZEB2 and E-cadherin was significantly and inversely associated in OSCC (χ^2^=10.365; P\<0.05) ([Table II](#tII-ol-0-0-6559){ref-type="table"}). Similarly, the expression of ZEB2 and E-cadherin was significantly and inversely associated in POT (χ^2^=4.219; P\<0.05) ([Table III](#tIII-ol-0-0-6559){ref-type="table"}).

### Association between ZEB2 and E-cadherin expression and clinicopathological factors

Further analysis indicated that the overexpression of ZEB2 in OSCC tissues was significantly associated with the depth of tumor invasion, lymph node metastasis and TNM stage (P\<0.05; [Table IV](#tIV-ol-0-0-6559){ref-type="table"}). By contrast, negative expression of membrane E-cadherin was significantly associated with lymph node metastasis (P=0.040; [Table IV](#tIV-ol-0-0-6559){ref-type="table"}). No significant associations were identified between expression of ZEB2 and clinicopathological variables, including sex, age, tumor position, tumor differentiation and tumor size (P\>0.05; [Table IV](#tIV-ol-0-0-6559){ref-type="table"}).

### Prognostic significance of ZEB2 and E-cadherin expression

In OSCC tissue, univariate analyses revealed significant associations between overall survival and ZEB2 overexpression (P=0.002), tumor size (P=0.011), depth of tumor invasion (P=0.002), lymph node metastasis (P\<0.0001) and TNM stage (P=0.004). By contrast, a lack of E-cadherin expression, poor differentiation, tumor site, age and sex were not significantly associated with prognosis ([Table V](#tV-ol-0-0-6559){ref-type="table"}). Kaplan-Meier analysis demonstrated that the median survival time for patients with ZEB2 overexpression in OSCC was 17.20 months, compared with 37.97 months for patients with OSCC and negative ZEB2 expression (P=0.003, log-rank test; [Table VI](#tVI-ol-0-0-6559){ref-type="table"}; [Fig. 3A](#f3-ol-0-0-6559){ref-type="fig"}). However, the median survival time for patients with OSCC and E-cadherin membrane expression was 24.00 months, compared with 34.00 months for patients with OSCC and negative E-cadherin expression (log-rank test, P=0.055; [Table VI](#tVI-ol-0-0-6559){ref-type="table"}). Notably, patients with ZEB2 overexpression and negative E-cadherin expression demonstrated decreased overall survival times (log-rank test, P=0.002; [Fig. 3B](#f3-ol-0-0-6559){ref-type="fig"}).

### Independent prognostic factors of OSCC

A multivariate analysis was performed to evaluate the variables that had been identified to be significant in the univariate analysis. The analysis indicated that overexpression of ZEB2 was an independent prognostic factor for favorable overall survival among patients with OSCC (hazard ratio, 1.568; 95% confidence interval, 1.084--2.269, P=0.017; [Table VI](#tVI-ol-0-0-6559){ref-type="table"}). Additionally, lymph node metastasis (P=0.001) was also identified to be an independent predictive factor for overall survival.

Discussion
==========

Highly invasive and metastatic behavior underlies the aggressive nature of OSCC, which in turn depends on EMT ([@b24-ol-0-0-6559]). Although a number of proteins, including ZEB2, have been reported to serve key roles in EMT, not all the proteins have been demonstrated to have prognostic significance in OSCC ([@b13-ol-0-0-6559]--[@b18-ol-0-0-6559],[@b24-ol-0-0-6559]--[@b29-ol-0-0-6559]). In the present study, ZEB2 expression was examined in a large number of samples taken from the invasive front of OSCC in order to assess its prognostic significance. The results indicate that ZEB2 is differentially expressed in OSCC and normal esophageal mucosal epithelium, and that ZEB2 expression is associated with shorter overall survival time ([@b30-ol-0-0-6559]).

Esophageal epithelial cells that have undergone EMT acquire functional characteristics of activated myofibroblasts *in vitro* ([@b31-ol-0-0-6559]). E-cadherin is a key component of adherence junctions that anchor esophageal epithelial cells ([@b32-ol-0-0-6559]). Loss of E-cadherin expression has been frequently reported in OSCC, particularly at the invasive tumor front ([@b10-ol-0-0-6559]) and is a recognized hallmark of EMT. The EMT phenotype can be controlled by the ZEB family of transcription factors, which is able to influence cell shape and adhesion, leading to an increased invasive potential ([@b33-ol-0-0-6559]). In the present study, ZEB2 was observed to be significantly overexpressed in \>35.3% of OSCC specimens. Consistent with the observations in the present study, ZEB2 has previously been reported to be overexpressed in several types of cancer, including OSCC ([@b29-ol-0-0-6559],[@b34-ol-0-0-6559]--[@b36-ol-0-0-6559]). Yoshida *et al* ([@b30-ol-0-0-6559]) reported increased ZEB2 expression in OSCC tissues compared with normal esophageal epithelium. ZEB2 controls the expression of matrix metalloproteinases ([@b37-ol-0-0-6559]) and other polarity proteins \[protein crumbs homolog 3and lethal ([@b2-ol-0-0-6559]) giant larvae protein homolog 2\] ([@b38-ol-0-0-6559]) and therefore may be regarded as a master regulator of the EMT process ([@b38-ol-0-0-6559]).

In the present study, it was demonstrated that there was an association between the ZEB2 expression and a number of clinicopathological parameters, including depth of tumor invasion, lymph node metastasis and TNM stage. By contrast, negative expression of membrane E-cadherin was significantly associated with lymph node metastasis. Notably, there was no association between the ZEB2 or E-cadherin expression and the degree of tumor differentiation, although ZEB2 expression has been previously reported to be associated with histological differentiation in gastric cancer ([@b39-ol-0-0-6559]). Similar to the present study, ZEB2 overexpression in various tumors (pancreatic cancer, eyelid sebaceous gland, pharyngeal squamous cell and oral squamous cell carcinoma) has been significantly associated with node metastasis ([@b34-ol-0-0-6559],[@b36-ol-0-0-6559],[@b40-ol-0-0-6559],[@b41-ol-0-0-6559]), although another previous study reported no such association ([@b42-ol-0-0-6559]). The association between decreased E-cadherin expression and lymph node metastasis remains unclear, and whether these inconsistent findings can be accounted for by the different type of pathogenesis remains to be investigated ([@b43-ol-0-0-6559],[@b44-ol-0-0-6559]).

The survival rate of patients with positive ZEB2 expression was significantly decreased compared with patients with negative expression in univariate and multivariate analysis. ZEB2 expression was associated with invasion and metastatic characteristics, and the overall survival rate would be expected to be lower in patients with these characteristics. The findings of the present study are similar to those of previous studies, which reported that that ZEB2 is associated with poor prognosis in patients with ovarian, mammary gland, renal cell, head and neck, and gastric carcinoma ([@b35-ol-0-0-6559],[@b45-ol-0-0-6559]--[@b48-ol-0-0-6559]). In the present study, ZEB2 was an independent prognostic factor for shorter survival time in postoperative patients with OSCC, which is also in agreement with previous findings ([@b40-ol-0-0-6559],[@b49-ol-0-0-6559],[@b50-ol-0-0-6559]).

It must be noted that, even though IHC techniques have become the focus of increasing attention, there remain a number of limitations. However, as the application of immunohistochemistry has increased, the estimated specificities to the antigens of the organ or tissue have remained comparable with some of the original expectations ([@b51-ol-0-0-6559]).

In summary, in the present study, it was demonstrated that ZEB2 and E-cadherin are frequently differentially expressed between OSCC and POT, and that ZEB2 and E-cadherin expression is associated with certain clinicopathological characteristics consistent with known biological function phenotypes. High ZEB2 expression in tumors is significantly and independently associated with poorer overall survival, particularly in patients with lymph node metastasis. Further studies are necessary to clarify the function of ZEB2 in EMT and to evaluate the prognostic significance of ZEB2.
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![ZEB2 and E-cadherin expression in OSCC tissues. Representative tissues exhibiting (A) strong positive ZEB2 expression, (B) moderately positive ZEB2 expression, (C) weakly positive ZEB2 expression, (D) negative ZEB2 expression, (E-G), negative E-cadherin expression and (H) positive E-cadherin expression at the cell membrane. Magnification, ×40 (left) and ×400 (right). OSCC, esophageal squamous cell carcinoma; ZEB2, zinc finger E-box-binding homeobox 2; E-cadherin, epithelial cadherin.](ol-14-03-2683-g00){#f1-ol-0-0-6559}

![E-cadherin and ZEB2 expression in peritumoral esophageal tissues. Magnification, ×40 (left) and ×400 (right). (A) E-cadherin expression was detected at the cell membrane of normal esophageal epithelial tissue. (B) A low level of ZEB-2 expression was identified in normal esophageal epithelial tissues. ZEB2, zinc finger E-box-binding homeobox 2; E-cadherin, epithelial cadherin.](ol-14-03-2683-g01){#f2-ol-0-0-6559}

![Prognosis and ZEB2 expression in patients with OSCC. (A) Kaplan-Meier analysis of overall survival rates for patients with OSCC and ZEB2 expression. (B) Kaplan-Meier analysis of overall survival rates for patients demonstrating different combinations of ZEB2 and E-cadherin expression. OSCC, esophageal squamous cell carcinoma; ZEB2, zinc finger E-box-binding homeobox 2; E-cadherin, epithelial cadherin.](ol-14-03-2683-g02){#f3-ol-0-0-6559}

###### 

Expression of ZEB2 and E-cadherin in esophageal tissue.

         ZEB2, n                E-cadherin, n                                                              
  ------ --------- ---- ------- ---------------------------------------------------- ------ ------ ------- ----------------------------------------------------
  OSCC   141       77   6.276   0.012^[a](#tfn1-ol-0-0-6559){ref-type="table-fn"}^   118    100    8.139   0.004^[b](#tfn2-ol-0-0-6559){ref-type="table-fn"}^
  POT      49      11                                                                  20     40           

Expression of ZEB2 in OSCC vs. POT.

Expression of E-cadherin in OSCC vs. POT. OSCC, esophageal squamous cell carcinoma; POT, peritumoral esophageal tissue; ZEB2, zinc finger E-box-binding homeobox 2; E-cadherin, epithelial cadherin.

###### 

Association between ZEB2 and E-cadherin immunoexpression in esophageal squamous cell carcinoma.

                                ZEB2 expression                 
  ----------------------------- ----------------- ---- -------- ----------------------------------------------------
  E-cadherin-positive (n=100)   24                76   10.365   0.001^[a](#tfn3-ol-0-0-6559){ref-type="table-fn"}^
  E-cadherin-negative (n=118)   53                65            

ZEB2 vs. E-cadherin immunoexpression in OSCC. ZEB2, zinc finger E-box-binding homeobox 2; E-cadherin, epithelial cadherin.

###### 

Association between ZEB2 and E-cadherin immunoexpression in peritumoral esophageal tissues.

                               ZEB2                
  ---------------------------- ------ ---- ------- ----------------------------------------------------
  E-cadherin-positive (n=40)   5      35   4.219   0.040^[a](#tfn4-ol-0-0-6559){ref-type="table-fn"}^
  E-cadherin-negative (n=20)   7      13           

ZEB2 vs. E-cadherin immunoexpression in POT. ZEB2, zinc finger E-box-binding homeobox 2; E-cadherin, epithelial cadherin.

###### 

Clinicopathological features of esophageal squamous cell carcinoma and associations with ZEB2 and E-cadherin immunoexpression.

                                          ZEB2, n                   E-cadherin, n                                                                
  -------------------------------- ------ --------- ------- ------- ---------------------------------------------------- ------- ------- ------- ----------------------------------------------------
  Sex                                                       0.020   0.889                                                                1.279   0.258
    Male                           183    118       65                                                                     96      87            
    Female                           35     23      12                                                                     22      13            
  Age, years                                                0.304   0.581                                                                0.266   0.206
    \<60                             47     32      15                                                                     27      20            
    ≥60                            171    109       62                                                                     91      80            
  Position                                                  0.615   0.735                                                                0.351   0.839
    Upper                            11       6         5                                                                    5       6           
    Middle                         185    120       65                                                                   101       84            
    Lower                            22   15          7                                                                    12      10            
  Differentiation                                           2.998   0.223                                                                4.058   0.131
    Well                             58     31      27                                                                     24      34            
    Moderately                       71     39      32                                                                     29      42            
    Poorly                           56   38        18                                                                     32      24            
  Diameter, cm                                              3.792   0.052                                                                0.914   0.339
    \<4                              97     63      24                                                                     56      41            
    ≥4                             121      78      53                                                                     62      59            
  T status                                                  4.104   0.043^[a](#tfn5-ol-0-0-6559){ref-type="table-fn"}^                   0.759   0.384
    T1-T2                            38     30        8                                                                    23      15            
    T3-T4                          180    111       69                                                                     95      85            
  N status                                                  10.64   0.001^[a](#tfn5-ol-0-0-6559){ref-type="table-fn"}^                   4.203   0.040^[a](#tfn5-ol-0-0-6559){ref-type="table-fn"}^
    Negative                       131      96      35                                                                     58      63            
    Positive                         87     45      42                                                                     60      37            
  TNM stage ([@b22-ol-0-0-6559])                            11.08   0.001^[a](#tfn5-ol-0-0-6559){ref-type="table-fn"}^                   0.390   0.533
    I and II                       104      79      25                                                                     54      50            
    III                            114      62      52                                                                     64      50            
  Total                            218    141       77                                                                   118     100             

Significantly associated parameters. ZEB2, zinc finger E-box-binding homeobox 2; TNM, tumor-node-metastasis; E-cadherin, epithelial cadherin.

###### 

Univariate analyses of ZEB2 expression and clinicopathological variables in 218 patients with esophageal squamous cell carcinoma (log-rank tests).

  Variable                                                 Total, n   Median survival, months   95% confidence interval   χ^2^     P-value
  -------------------------------------------------------- ---------- ------------------------- ------------------------- -------- ----------------------------------------------------
  Sex                                                                                                                     0.363    0.547
    Male                                                   183        26.97                     18.04--35.90                       
    Female                                                   35       34.00                     20.38--45.39                       
  Age, years                                                                                                              1.963    0.136
    \<60                                                     47       48.47                     32.15--64.79                       
    ≥60                                                    171        24.00                     15.99--32.01                       
  Position                                                                                                                3.137    0.208
    Upper                                                    11       15.00                     6.80--23.20                        
    Middle                                                 185        26.97                     18.12--35.83                       
    Lower                                                    22       56.80                     34.20--79.40                       
  Differentiation                                                                                                         4.049    0.129
    Well                                                     58       35.46                     23.46--48.55                       
    Moderately                                               71       21.78                     12.89--30.17                       
    Poorly                                                   56       18.95                     9.74--25.67                        
  Diameter, cm                                                                                                            6.447    0.01^[a](#tfn6-ol-0-0-6559){ref-type="table-fn"}^
    \<4                                                      97       36.00                     20.19--51.81                       
    ≥4                                                     121        20.00                     9.13--30.87                        
  T status ([@b22-ol-0-0-6559])                                                                                           9.781    0.002^[a](#tfn6-ol-0-0-6559){ref-type="table-fn"}^
    T1-T2                                                    38       70.10                     45.89--94.31                       
    T3-T4                                                  180        20.73                     12.26--29.20                       
  N status ([@b22-ol-0-0-6559])                                                                                           17.722   0.000^[a](#tfn6-ol-0-0-6559){ref-type="table-fn"}^
    Negative                                               131        43.47                     26.98--59.96                       
    Positive                                                 87       15.13                     11.88--18.38                       
  ^[b](#tfn7-ol-0-0-6559){ref-type="table-fn"}^TNM stage                                                                  8.210    0.004^[a](#tfn6-ol-0-0-6559){ref-type="table-fn"}^
    I and II                                               104        43.47                     23.95--62.99                       
    III                                                    114        18.10                     13.01--23.19                       
  ZEB2 expression                                                                                                         9.095    0.002^[a](#tfn6-ol-0-0-6559){ref-type="table-fn"}^
    Negative                                                 77       37.97                     25.08--50.86                       
    Positive                                               141        17.20                     13.06--21.34                       
  E-cadherin expression                                                                                                   3.685    0.055
    Positive                                               100        24.00                     14.69--33.31                       
    Negative                                               118        34.00                     4.72--63.28                        

Significantly associated parameters.

National Comprehensive Cancer Network guidelines. TNM, tumor-node-metastasis; ZEB2, zinc finger E-box-binding homeobox 2; E-cadherin, epithelial cadherin.

###### 

Multivariate Cox\'s regression analysis of overall survival in patients with esophageal squamous cell carcinoma.

                                                                                                          Multivariate analysis                                    
  ------------------------------------------------------------------------------------------------------- ----------------------- --------- ------- -------------- ----------------------------------------------------
  Diameter (\<4 vs. ≥4 cm)                                                                                0.346                     3.836   1.414   1.000--1.999   0.050
  T statu) (positive vs. negative)                                                                        0.853                   11.776    2.346   1.441--3.817   0.001^[a](#tfn8-ol-0-0-6559){ref-type="table-fn"}^
  ^[b](#tfn9-ol-0-0-6559){ref-type="table-fn"}^TNM stage (I ands ([@b22-ol-0-0-6559]) (T1-T2 vs. T3-T4)   0.455                     0.264   1.576   0.094--2.572   0.085
  N status (22 II vs. III)                                                                                0.338                     3.839   1.402   1.000--1.965   0.050
  ZEB2 expression (positive vs. negative)                                                                 0.450                     5.707   1.568   1.084--2.269   0.017^[a](#tfn8-ol-0-0-6559){ref-type="table-fn"}^

Significantly associated parameters.

National Comprehensive Cancer Network guidelines. TNM, tumor-node-metastasis; ZEB2, zinc finger E-box-binding homeobox 2.
